Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study

Wolfram E. Samlowski, James Moon, J. Philip Kuebler, Craig R. Nichols, David R Gandara, Howard Ozer, Stephen K. Williamson, James N. Atkins, David E. Schuller, John F. Ensley

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

Original languageEnglish (US)
Pages (from-to)182-188
Number of pages7
JournalCancer Investigation
Volume25
Issue number3
DOIs
StatePublished - Apr 2007

Fingerprint

docetaxel
Carboplatin
Neutropenia
Disease-Free Survival
Area Under Curve
Outpatients
Drug Therapy
Survival
Carcinoma, squamous cell of head and neck

Keywords

  • Carboplatin
  • Chemotherapy
  • Docetaxel
  • Head and neck cancer
  • Taxane

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) : A Southwest Oncology Group phase II study. / Samlowski, Wolfram E.; Moon, James; Kuebler, J. Philip; Nichols, Craig R.; Gandara, David R; Ozer, Howard; Williamson, Stephen K.; Atkins, James N.; Schuller, David E.; Ensley, John F.

In: Cancer Investigation, Vol. 25, No. 3, 04.2007, p. 182-188.

Research output: Contribution to journalArticle

Samlowski, Wolfram E. ; Moon, James ; Kuebler, J. Philip ; Nichols, Craig R. ; Gandara, David R ; Ozer, Howard ; Williamson, Stephen K. ; Atkins, James N. ; Schuller, David E. ; Ensley, John F. / Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) : A Southwest Oncology Group phase II study. In: Cancer Investigation. 2007 ; Vol. 25, No. 3. pp. 182-188.
@article{00d8ebd40bec41d3a5a2c82776896752,
title = "Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study",
abstract = "Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95{\%}CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95{\%}CI, 3.1-4.8) Median overall survival was 7.4 months (95{\%}CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.",
keywords = "Carboplatin, Chemotherapy, Docetaxel, Head and neck cancer, Taxane",
author = "Samlowski, {Wolfram E.} and James Moon and Kuebler, {J. Philip} and Nichols, {Craig R.} and Gandara, {David R} and Howard Ozer and Williamson, {Stephen K.} and Atkins, {James N.} and Schuller, {David E.} and Ensley, {John F.}",
year = "2007",
month = "4",
doi = "10.1080/07357900701209061",
language = "English (US)",
volume = "25",
pages = "182--188",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)

T2 - A Southwest Oncology Group phase II study

AU - Samlowski, Wolfram E.

AU - Moon, James

AU - Kuebler, J. Philip

AU - Nichols, Craig R.

AU - Gandara, David R

AU - Ozer, Howard

AU - Williamson, Stephen K.

AU - Atkins, James N.

AU - Schuller, David E.

AU - Ensley, John F.

PY - 2007/4

Y1 - 2007/4

N2 - Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

AB - Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

KW - Carboplatin

KW - Chemotherapy

KW - Docetaxel

KW - Head and neck cancer

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=34347270591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347270591&partnerID=8YFLogxK

U2 - 10.1080/07357900701209061

DO - 10.1080/07357900701209061

M3 - Article

C2 - 17530488

AN - SCOPUS:34347270591

VL - 25

SP - 182

EP - 188

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -